DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Langerhans cell sarcoma — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLangerhans cell sarcoma maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for langerhans cell sarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
B-Raf proto-oncogene, serine/threonine kinase (BRAF) — BRAF is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet agsdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8VYP · 3.29 Å · ligand PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER (AGS). Experimental structure, not a prediction.
What the evidence adds up to
A 2019 case report describes a 41-year-old patient whose Langerhans cell sarcoma arose from antecedent Langerhans cell histiocytosis 11 months after excision of a benign groin mass. The patient received six cycles of a modified E-CHOP regimen (etoposide, cyclophosphamide, vindesine, dexamethasone) and was still in follow-up at the time of writing. The authors call E-CHOP an effective first-line therapy but state the mechanism is unclear and that further data on clinical outcomes are necessary to establish optimal treatment.
A 2020 case report describes a young patient with fulminant metastatic Langerhans cell sarcoma who achieved persistent remission after polychemotherapy followed by high-dose chemotherapy with autologous stem cell transplantation. Fewer than 100 cases had been described in the English literature at that time, and the clinical course is called extremely aggressive with poor survival rates, especially in disseminated disease.
A 2015 study examined Wilms tumor 1 (WT1) and CD44 as potential diagnostic biomarkers for Langerhans cell sarcoma. The tumour cells expressed WT1, CD44, and the standard Langerhans cell markers langerin, CD1a, and S-100 protein, but all cases showed normal cytogenetic findings without overexpression of WT1 and CD44. The authors suggest these markers may help distinguish LCS from Langerhans cell histiocytosis and other malignancies, but the functional roles remain unclear.
No controlled trials exist for this disease. What is missing is any prospective trial design, any patient stratification strategy, and any dedicated funding for a sarcoma so rare that fewer than 100 cases have been published.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Medicine · 2019 · 23 citations · open access
Langerhans cell sarcoma arising from antecedent langerhans cell histiocytosis
AbstractRATIONALE: Langerhans cell sarcoma (LCS) is a rare, high-grade neoplasm characterized by overtly malignant cytologic features and a poor prognosis. Herein, we present a rare case of langerhans cell histiocytosis (LCH) that later transformed into langerhans cell sarcoma 11 months after the benign mass was excised from soft tissue in the right groin. PATIENT CONCERNS: A 41-year-old patient who presented with a mass in the right groin for 3 years earlier after being bitten by ants. DIAGNOSES: The patient was diagnosed with langerhans cell sarcoma arising from antecedent langerhans cell histiocytosis. INTERVENTIONS: The patient underwent with 6 cycles of a modified etoposide, cyclophosphamide, vindesine, dexamethasone (E-CHOP) regimen. OUTCOMES: The patient is currently receiving follow-up care. LESSONS: LCH transformed into LCS is a rare case. E-CHOP as an effective first-line therapy to treat LCS cases, but, the mechanism is unclear. Due to their rarity, further data on clinical outcomes are necessary to establish the optimal treatment strategy for LCS.
Diagnostic Value of Wilms Tumor 1 and CD44 in Langerhans Cell Sarcoma
AbstractLangerhans cell sarcoma (LCS) is a rare tumor with markedly malignant cytological features originating from Langerhans cells. LCS diagnosis is difficult and requires differentiation from other malignant tumors and Langerhans cell histiocytosis (LCH). Immunochemical antibodies, such as langerin, S-100 protein, and CD1a, have been used to diagnose LCS, but the results are crossed with LCH. To determine more significant biomarkers of LCS, we studied the expression and distribution pattern of Wilms tumor 1 (WT1) and cluster of differentiation 44 (CD44) in LCS. A broad panel of antibodies was used for immunohistochemical technology. Simultaneously, dual immunofluorescence staining examination and fluorescence in situ hybridization staining methods were used to study the location of WT1 and CD44 in LCS tumor cells. The results showed that tumor cells expressed WT1, CD44, and other special Langerhans cell markers (langerin, CD1a, and S-100 protein). LCS cells in all the cases showed normal cytogenetic findings without overexpression of WT1 and CD44. The expression of WT1 and CD44 was observed on langerin tumor cells by dual immunofluorescence staining examination in LCS. Our results suggest that WT1 and CD44 are potential biomarkers for LCS diagnosis. Clear understanding of their functional roles may further explain the pathogenesis of this highly malignant tumor and develop some novel immunotherapy strategies.
memo - Magazine of European Medical Oncology · 2020 · 0 citations · open access
Complete remission of disseminated Langerhans cell sarcoma after stem cell transplantation
AbstractSummary With fewer than 100 cases described in the English literature so far, Langerhans cell sarcoma represents an orphan malignant disease deriving from histiocytic cells. Clinical course is extremely aggressive and associated with poor survival rates, especially in disseminated condition. Herein, we describe the case of a young patient with fulminant development of metastatic Langerhans cell sarcoma, who achieved persistent remission after polychemotherapy and subsequent high-dose chemotherapy with autologous stem cell transplantation.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
